State of Medtech

The biggest opportunity in cardiovascular AI may come from revealing risk that conventional imaging does not fully explain. Omar Khateeb sits down with Steve Deitsch, CEO of Caristo Diagnostics, to discuss CaRi-Heart, an FDA-authorized AI technology that quantifies coronary inflammation from routine CCTA imaging. Before Caristo, Steve served as CFO of OrganOx and helped lead its $1.5 billion acqui...

In this episode, Omar Khateeb sits down with Henry Peck, Chief Business Officer at LSI, for a September and October edition of This Month in MedTech covering major exits, surgical robotics, regulatory shifts, and strategic capital. More than $4 billion in European MedTech exits set the stage. Henry shares LSI data showing that 77% of more recent LSI Europe companies are pursuing an FDA-first pathw...

MedTech may be entering an era where the most valuable companies are built as platforms. Omar Khateeb sits down with Nick Damiano of Andromeda Surgical and Dave Messina of Pioneer Fund to explore TechMed, autonomous surgery, VC, and startups. Nick explains how software, regulation, focused use cases, and rapid feedback can make MedTech more scalable. Andromeda starts narrow and builds toward broad...

a16z says physical technology is becoming important again. What could that mean for MedTech? Omar Khateeb analyzes a16z’s State of Markets 2026 report and explores how AI, robotics, infrastructure, and changing venture economics could reshape the investment case for medical technology. One theme stands out: capital is moving into industries that require hardware, manufacturing, infrastructure, and...

Space exploration may be approaching a bottleneck: the human body. Omar Khateeb speaks with Matthew Kuhn, CEO of Skybound Medtech, to explore space medicine, autonomous care and robotics. Microgravity accelerates muscle and bone loss, while deep-space communication delays can make real-time support from Earth impractical. They discuss autonomous surgery, physical AI, reusable devices, remote diagn...

Surgical demand keeps rising, but the answer may not be more rooms, staff, or complex robotic systems. Omar Khateeb sits down with Jeffery Alvarez, Chief Strategy Officer at Moon Surgical, to explore Scalable Surgery and how physical AI, workflow design, and ASC economics could reshape surgical robotics. Jeffery explains why healthcare needs better execution, not simply more capacity. ASCs use spe...

Remote surgery becomes far more interesting when you stop thinking about moving a robot and start thinking about moving expertise. In this episode, Omar Khateeb sits down with Brian Miller, CEO of SOVATO, to explore how remote procedures could reshape specialized care. Brian explains why robotics is only one part of the equation. It depends on secure infrastructure, reliable connectivity, clinical...

In this episode, Jacob McLaughlin welcomes Omar Khateeb for a conversation about medical device sales, MedTech leadership, entrepreneurship, market strategy, and building long-term career leverage. Omar shares how his career evolved from surgical robotics and medical device sales into marketing, Silicon Valley, entrepreneurship, and MarketCraft, where he focuses on MedTech market engineering for e...

In this episode, Omar Khateeb speaks with Sudhir Srivastava, MD, Founder, Chairman & CEO of SS Innovations International Inc., on how surgical robotics and telesurgery could reshape access to care. Dr. Srivastava shares his journey from cardiac surgeon to MedTech founder and the development of the SSi Mantra surgical robotic platform, built to make robotic surgery more affordable and accessibl...

In this solo episode, Omar Khateeb explains why MedTech founders should stop treating social media like traditional marketing and start using it as a market engineering tool to build investor demand, clinical credibility, strategic awareness, and talent attraction. Most companies begin outreach only when they need something. Investors hear from the company during a fundraise, physicians when adopt...

In this episode, Omar Khateeb speaks with Jenny Barba and Jeff Chu, Co-Founders, Features Capital, about what makes an early-stage MedTech company investable before first-in-human data or meaningful revenue. Features Capital often invests $500,000 to $2 million at this stage. Jenny and Jeff explain why investors look beyond technology to founder execution, technical feasibility, clinical adoption,...

In this solo episode, Omar Khateeb explores why QSBS could become an overlooked capital formation tool in MedTech . QSBS was created to encourage investment in small American businesses, and Omar explains why it may fit MedTech investing well. Medical device companies often require years of engineering, clinical development, FDA review, reimbursement, manufacturing, and commercialization before in...

In this episode, Omar Khateeb speaks with Aneta Sottil, Partner at Andera Partners, about what makes a MedTech company investable as the investment bar continues to rise. Aneta explains why early data is often no longer enough. Investors increasingly want stronger clinical validation, a clear path to market, reimbursement strategy, and proof that a technology can meaningfully improve patient care....

Explore Showpad's VIP event, Excellence in the Field, in New York on October 8, 2026, for revenue leaders seeking practical AI and sales insights. Learn more . In this episode, Omar Khateeb speaks with Gavin Leonard, CEO of MedTech Syndicates, and Steven Kaplan, Director of the American Urological Association Innovation Nexus, to explore how clinical insight, capital and commercialization can...

In this episode, Omar Khateeb speaks with Virginia Giddings, Vice President of Exploration at Edwards Lifesciences , about how major MedTech companies evaluate startups before commercial scale. Virginia explains why Edwards builds early relationships in structural heart and heart failure, assessing patient need, clinical evidence, reimbursement, and strategic fit. She shares why founders need conv...

In this episode, Omar Khateeb speaks with David Hochman, Chairman & CEO of Orchestra BioMed, about a partnership-driven model for building, funding, and commercializing MedTech innovation. Orchestra focuses on intellectual property, clinical development, and pivotal execution while partnering with global strategics that already have the infrastructure to manufacture, commercialize, and scale....

In this episode of This Month in MedTech, Omar Khateeb speaks with Henry Peck, CBO at LSI | Intelligence, about the technologies, deals, and shifts shaping MedTech. They examine Vitestro’s FDA authorization for autonomous blood draws, bringing physical AI into a high-volume workflow within the roughly $220 billion clinical laboratory services market. The technology could expand capacity, improve a...

In this episode, Omar Khateeb speaks with Eric S. Heinz, Founder and Managing Partner of Heinz Ventures, about creating MedTech value through product development, financing, commercialization, and strategic acquisition. Eric brings 25 years of experience at Medtronic and Intuitive Surgical. His operating and M&A background shapes how he evaluates pre-seed and seed-stage companies. A major them...

In this solo episode, Omar Khateeb examines why healthcare could become one of the most important beneficiaries of the next phase of AI, even as investors increasingly view the sector as a defensive alternative to the AI infrastructure trade. The central distinction is between building intelligence and deploying intelligence . Healthcare already produces enormous amounts of medical imaging, ECG da...

In this episode, David Niewolny, Sr. Director and Global Head of Business Development for Healthcare and Medical at NVIDIA , joins Omar Khateeb to discuss how simulation, AI, open-source development, and GPU-scale computing are changing the way medical robots are built and trained. Healthcare robotics has an experience problem. Anatomy varies between patients, devices bend and interact with tissue...

In this solo episode, Omar Khateeb translates some of Uber founder Travis Kalanick’s strongest lessons on fundraising, scale, leadership, and resilience into practical ideas for MedTech founders. The discussion begins with a powerful operating principle: companies can only scale as quickly as their organizations can solve the problems created by growth. FDA clearance, new indications, commercializ...

In this episode, Dr. Amir Reuveny, Founder and CEO of Wesper , joins Omar Khateeb to unpack why sleep diagnostics are becoming increasingly important as the treatment landscape for sleep apnea expands. Amir shares how watching his father struggle with unrecognized sleep apnea eventually connected with his academic work in flexible electronics, leading him to build technology designed around comfor...

Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNfJoin Omar at Medtech CEO Camp in Boston. Use code MC1000 for $1,000 off. https://www.campcuriae.com/ In this solo episode, Omar Khateeb explains why most MedTech investor decks fail to create conviction and how founders can build presentations that make the market opportunity, adoption path, and use of capita...

In this episode, Omar Khateeb speaks with Amy Kruse, General Partner and Chief Investment Officer at Satori Neuro, about the intersection of neuroscience, neurotechnology, AI, brain health innovation, and venture capital. A neuroscientist, DARPA leader, defense executive, entrepreneur and investor, Amy explains Satori Neuro's ecosystem approach. Interests include neuromodulation, precision psy...

In this solo episode, Omar Khateeb examines Peter Thiel’s most overlooked lesson for MedTech founders: breakthrough technology does not create its own path to customers, investors, clinicians, or commercial adoption. Drawing from the sales and distribution chapter of Zero to One , Omar explains why commercialization begins long before FDA clearance or product launch. A MedTech company is already s...